Table Of Content

AUTHOR INDEX AND CUMULATIVE TABLE OF CONTENTS CUMULATIVE TABLE OF CONTENTS, VOLUME 17 Number 1 Number 3 THROMBOLYSIS OF ACUTE AND CHRONIC ARTERIAL CELL BIOLOGY OF FIBRINOLYSIS OCCLUSIONS Hau C. Kwaan, M.D., and Gabor Markus, M.D., Ph.D. Michael Martin, M.D. Fibrinolysis: Past and Present, a Reflection of Fifty Years, Tage Fibrinolytic Therapy: Biochemical Mechanisms, Kenneth C. Rob- Astrup, Dr. Scient., Dr. Med. h.c. bins, Ph.D. Components of the Plasminogen-Plasmin System in Human Tumor Thrombolysis in Arterial Bypass Grafts, Arina van Breda, M.D. Cell Lines, Hau C. Kwaan, M.D., Harold N. Keer, M.D., James A. Local Thrombolysis for Salvage of Occluded Bypass Grafts, Klaus Radosevich, Ph.D., Jean-Francois Cajot, M.D., and Robin Ernst, Mathias, M.D. B.S. Short-Term Ultrahign Streptokinase Treatment of Chronic Arte- Protein Structure and Membrane Anchorage of the Cellular rial Occlusions and Acute Deep Vein Thromboses, Michael Receptor for Urokinase-Type Plasminogen Activator, Michael Martin, M.D., and B.J. Othmar Fiebach, M.D. Ploug, Ph.D., Niels Behrendt, Ph.D., Dorte Lober, M.S., and Keld Intra-Arterial Fibrinolytic Therapy of Chronic Arterial Occlu- Dang, M.D. sions, Franz-Joseph Roth, M.D., Rudolf Rieser, M.D., Anders Plasminogen Activation by Receptor-Bound Urokinase, Vincent Scheffler, M.D., and Wolfgang Krings, M.D. Ellis, Ph.D., and Keld Dang, M.D. Fibrinolytic Therapy of Deep Vein Thrombosis with Continuous Stimulation of Cell Surface Plasminogen Activation by Heparin Intravenous Infusion of a Recombinant Tissue Plasminogen and Related Polyionic Substances, Ross W. Stephens, Ph.D., Jari Activator, Rainer Zimmerman, M.D., Abdulkadir Giirsoy, M.D.., Péllanen, M.D., Hannele Tapiovaara, M.Sc., Graeme Woodrow, Andreas Horn, M.D., Job Harenberg, M.D., Curt Diehm, M.D., Ph.D., and Antti Vaheri, M.D., Ph.D. and Wolfgang, Kiibler, M.D. Plasminogen Activators in Epithelial Biology, Gerald S. Lazarus, Factor XI: A Review of Its Biochemistry and Deficiency, Craig S. M.D., and Pamela J. Jensen, Ph.D. Kitchens, M.D. Epidermal Growth Factor and 12-Tetradecanoyl Phorbol 13- Abstracts of Current Literature, Rodger L. Bick, M.D., F.A.C.P., Acetate Induction of Urokinase in A431 Cells, Timothy L. Genesio Murano, Ph.D., Meyer M. Samama, M.D., and Ernst Kessler, Ph.D., and Gabor Markus, M.D., Ph.D. Wenzel, M.D., Editors Urokinase-Dependent Proteolysis in Cultured Colon Cancer Is Directed by Its Receptor, William Hollas, B.A., and Douglas Number 2 Boyd, Ph.D. HIRUDIN Growth Factors in the Regulation of Plasminogen-Plasmin System Fritz Markwardt, M.D., Ph.D. in Tumor Cells, Jorma Keski-Oja, M.D., Katri Koli, M.Sc., Jouko Lohi, B.M., and Marikki Laiho, M.D. The Comeback of Hirudin as an Antithrombotic Agent, Fritz Tumor Necrosis Factor Stimulates Urokinase-Type Plasminogen Markwardt, M.D., Ph.D. Activator and Inhibitor Type 1 Production in A549 Lung Isolation and Characterization of Hirudin from Hirudo medicinalis, Carcinoma Cells: Treatment of Monolayer and Tridimensional Peter Walsmann, Ph.D. Cultures, Anne-Marie Dosne, Ph.D., René Beaupain, Ph.D., and Recombinant Hirudin: Genetic Engineering and Structure Analy- Meyer Samama, M.D. sis, Walter E. Marki, Hugo Grossenbacher, Markus G. Griitter, Function of Receptor-Bound Urokinase, Johannes C. Kirchheimer, Manfred H. Liersch, Bernd Meyhack, and Jutta Heim M.D., and Bernd R. Binder, M.D. Structure-Activity Relationships of Recombinant Hirudins, Jorg Enhanced Activation of Prourokinase by Human RC2A Leukemia Stiirzebecher, Ph.D., and Peter Walsmann, Ph.D. Cells, Hannele Tapiovaara, M.Sc., Antti Vaheri, M.D., Ph.D., Methods for Determination of Hirudin, Jérg Stiirzebecher, Ph.D. Riitta Alitalo, M.D., Ph.D., Pheng-Siew Sim, Ph.D., Graeme Comparative Studies on Various Assays for the Laboratory Eval- Woodrow, Ph.D., and Ross W. Stephens, Ph.D. uation of r-Hirudin, Jeanine M. Walenga, Ph.D., MT (ASCP), Modulation of Surface-Associated Urokinase in Different Cell Debra Hoppensteadt, M.S., MT (ASCP), Michael Koza,-B.S., MT Lines: Evidence for Urokinase Interiorization and Degradation, (ASCP), Roque Pifarre, M.D., and Jawed Fareed, Ph.D. Mario Del Rosso, M.D., Gabriella Fibbi, Ph.D., Germana Dini, Laboratory Use of Hirudin, Kurt Stocker, Ph.D. hon. Ph.D., Cecilia Grappone, Ph.D. and Marco Pucci, Ph.D. Hirudin and Platelets, Erika Glusa, M.D. Regulation of Plasminogen Activator and Plasminogen Activator Toxicology of Hirudin, Hans-Peter Klécking, M.D., D.Sc. Inhibitor Expression by Cells of Neural Origin, Patricia G. Anticoagulant and Antithrombotic Actions of Recombinant Hiru- Murphy, Ph.D., and David A. Hart, Ph.D. din, Brigitte Kaiser, M.D. Plasminogen Activator Inhibitor in Stomach and Colorectal Car- Neutralization of Recombinant Hirudin: Some Practical Consider- cinomas, Hideharu Fukao, Ph.D., Nobuya Tanaka, M.D., Shigeru ations, Jawed Fareed, M.D., Jeanine M. Walenga, Ph.D., Debra Ueshima, M.D., Ph.D., Kiyotaka Okada, Ph.D., Masayuki Yasu- Hoppensteadt, M.S., Lalitha lyer, B.S., and Roque Pifarre, M.D. tomi, M.D., Ph.D., and Osamu Matsuo, M.D., Ph.D. Pharmacokinetics of Hirudin, Goetz Nowak, M.D. Fibrinolytic Profiles in Patients with Small Cell Carcinoma of the Report on a Discussion Forum: “Medical and Surgical Application Lung, Takeshi Wajima, M.D., Ph.D. of Recombinant Hirudin’”’, Jeanine M. Walenga, Ph.D., Fritz Hormone Regulation of Tissue-Type Plasminogen Activator Gene Markwardt, M.D., Klaus Breddin, M.D., Jawed Fareed, M.D. Expression and Plasminogen Activator-Mediated Proteolysis, (Organizing Committee) Monica Ohlsson, B.S., Xiao-Rong Peng, M.S., Yi-Xun Liu, Ph.D., Scholarly Potpourri, Ernst Wenzel, M.D. Xiao-Chi Jia, B.S., Aaron J.W. Hsueh, Ph.D., and Tor Ny, Ph.D. 484 SEMINARS IN THROMBOSIS AND HEMOSTASIS—VOLUME 17, NO. 4, 1991 Fluorescent Probes as Tools to Assess the Receptor for the Plasminogen Activator Release, Hans-Peter Klécking, M.D., Urokinase-Type Plasminogen Activator on Tumor Cells, Man- D.Sc., Anna Hoffmann, D.Sc., and Jawed Fareed, Ph.D. fred Schmitt, Ph.D., Nikolaus Chucholowski, Pharm., Elisabeth Advantages of Low Molecular Weight Heparin over Standard Busch, BTA, Daniela Hellmann, VMTA, Bettina Wagner, Dipl. Heparin: Facts and Fiction, Helmut Vinazzer, M.D. Biol., Lothar Goretzki, Dipl. Biol., Fritz Janicke, M.D., Wolfgang Effect of Heparin on the Fibrinolytic Response to Plasminogen A. Giinzler, Ph.D., and Henner Graeff, M.D. Activators, Robin Fears, Ph.D., Ashiq F. Esmail, Ph.D., and Helen Clinical Relevance of the Urokinase-Type and Tissue-Type Plas- C. Greenwood, M.I. Biol. minogen Activators and of Their Type 1 Inhibitor in Breast Effect of Pentosan Polysulfate on Activated Partial Thromboplastin Cancer, Fritz Janicke, M.D., Manfred Schmitt, Ph.D., and Henner Time, Thrombin Time, Euglobulin Clot Lysis, and on Tissue- Graeff, M.D Type Plasminogen Activator and Plasminogen Activator Inhib- Abstracts of Current Literature, Rodger L. Bick, M.D., F.A.C.P., itor Activities in Patients with Thromboembolic Disease, Hajna Genesio Murano, Ph.D., Meyer M. Samama, M.D., and Ernst Losonezy, M.D., Ph.D., Marianna David, M.D., and Ibolya Nagy, Wenzel, M.D., Editors M.D., Ph.D. Scholarly Potpourri, Genesio Murano, Ph.D. Enhancement by Defibrotide of Prostanoid Neosynthesis from Arachidonic Acid: An Adenosine Receptor-Mediated Effect?, Giorgio Bianchi, M.D., Angelo Benvenuto Calvani, Marisa Manto- vani, M.D., and Giuseppe Prino, M.D. Number 4 Absorption Through the Peritoneum of the Macromolecular Profi- THROMBOSIS AND FIBRINOLYSIS: CURRENT CLINICAL brinolytic Drug Defibrotide in the Rabbit, Roberto Porta, Ph.D.., AND THERAPEUTIC ASPECTS Angelo Benvenuto Calvani, Rodolfo Pescador, Ph.D., Marisa Jawed Fareed, Ph.D., Hau C. Kwaan, M.D., Mantovani, M.D., and Giuseppe Prino, M.D. Pan Ganguly, M.D., Jeanine M. Walenga, Ph.D., Fibrinolytic Activity in Patients with Diabetes Mellitus: Charac- H. Klaus Breddin, M.D., and Antonio Strano, M.D. terization of the Effects of Thrombolytic Agents on Plasma Clot Lysis In Vitro, Robin Fears, Ph.D., Ruth Standring, Ph.D., and Venous Thromboprophylaxis in the 1990s: A Perspective, Jawed Ralph Abraham, Ph.D., B.M., B.Ch., M.R.C.P. Fareed, Ph.D. Induction and Possible Role of Fibrinolysis in Diabetes Mellitus, International Perspective on Venous Thromboembolism Prophy- Jgrgen Gram, M.D., D.Sc., and Jorgen Jespersen, M.D., D.Sc. laxis in Surgery, Juan |. Arcelus, M.D., Ph.D., Joseph A. Caprini, Plasminogen Activation in Diabetes Mellitus: Kinetics of Plasmin M.D., F.A.C.S., and Clara |. Traverso, M.D., Ph.D. Formation with Plasminogen and Tissue Plasminogen Activator Is Pulmonary Embolism a Suitable Evaluation Criterion of the from Diabetic Donors, Margarethe Geiger, M.D., and Bernd R. Efficacy of Prophylactic Treatment in Surgery?, Francis Toulem- Binder, M.D. onde, M.D., and Christian Doutremepuich, M.D. In Vivo Platelet Activation in Diabetes Mellitus, Antonio Strano, Current Trends in the Management of Postsurgical Thromboem- M.D., Giovanni Davi, M.D., and Carlo Patrono, M.D. bolism: The Role of Low Molecular Weight Heparin, David Nonenzymatic Glycation of Platelet Proteins in Diabetic Patients, Bergqvist, M.D., Ph.D. Isaac Cohen, Ph.D., Dan L. Burk, M.Sc., Ruth Fullerton, Arthur Thromboprophylaxis with Heparin and Low Molecular Weight Veis, Ph.D., and David Green, M.D., Ph.D. Heparin in Elective Hip Surgery: Current Status and Perspec- Large Platelets Circulate in an Activated State in Diabetes Mellitus, tives, Hans Georg Breyer, M.D. D. Tschoepe, M.D., P. Roesen, J. Esser, B. Schwippert, H.K. Comparison of the Efficacy and Safety of Sandoz Low Molecular Nieuwenhuis, B. Kehrel, and F.A. Gries Weight Heparin and Unfractionated Heparin: Interim Analysis Clinical Trials of Antiplatelet Agents in Diabetes Mellitus: Ratio- of a Multicenter Trial, Helmut Wolf, M.D., Albrecht Encke, nale, and Results, John A. Colwell, M.D., Ph.D. M.D., Sylvia Haas, M.D., and Dieter Welzel, M.D. Modifications of Monocyte Procoagulant Activity in Diabetes Prevention of Thromboembolism After Spinal Cord Injury, Dav- Mellitus, Brigitte Jude, M.D., and Pierre Fontaine, M.D. id Green, M.D., Ph.D. Diabetic Capillary Angiopathy of the Dermis of the Hand and Foot Can the Bleeding Potential of Low Molecular Weight Heparins be in Patients with Diabetes Mellitus, Panagiotis Balas, M.D. Assessed and Minimized in Postsurgery Prophylaxis?, Francis Biologic Tolerance of Two Different Low Molecular Weight Hep- Toulemonde, M.D. arins, Hanne M. Christiansen, M.D., Michael R. Lassen, M.D., Low Molecular Weight Heparins and External Pneumatic Com- Lars C. Borris, M.D., Jens V. Sgrensen, M.D., Hans B. Rahr, pression as Options for Venous Thromboembolism Prophylaxis: M.D., Lars N. Jorgensen, M.D., Peer W. Jorgensen, M.D., and Ole A Surgeon’s Perspective, Joseph A. Caprini, M.D., F.A.C.S., Hauch, M.D. Juan I. Arcelus, M.D., Ph.D., Clara I. Traverso, M.D., Ph.D., and Some Objective Considerations for the Use of Heparins and James H. Hasty, Ph.D. Recombinant Hirudin in Percutaneous Transluminal Coronary A Pilot Study on the Use of a Low Molecular Weight Heparin Angioplasty, Jawed Fareed, Ph.D., Jeanine M. Walenga, Ph.D., F. (Enoxaparin) in Arterial Reconstructive Surgery, Charles Marc Leya, M.D., P. Bacher, M.D., Debra Hoppensteadt, M.S., Harry Samama, M.D., Eric Barre, M.D., Sophie Combe, M.D., Sophie Messmore, M.D., and Roque Pifarre, M.D. Dreux, M.D., Edouard Kieffer, M.D., and Pierre Viars, M.D. Report on the Chicago Satellite Symposia of the Xth International Heparins and Stroke: Is There a Place for Low Molecular Weight Congress of Fibrinolysis, August 2-4, 1990 Heparins?, William S. Fields, M.D. Abstracts of Current Literature, Rodger L. Bick, M.D., F.A.C.P., Effect of Pentosan Polysulfate on Fibrinolysis: Basic Tests and Genesio Murano, Ph.D., Meyer M. Samama, M.D., and Ernst Clinical Application, Helmut Vinazzer, M.D. Wenzel, M.D., Editors Influence of Hypersulfated Lactobionic Acid Amides on Tissue Author Index and Cumulative Table of Contents, Volume 17